Speaking with Shadd Dales of The Dales Report, Eric A. Adams, CEO of InMed, discusses the market differences between developing and commercializing a cannabinoid for pharmaceutical purposes or for the health and wellness sector.
Read the article and watch the full video at The Dales Report.
In this article published in Gene Online September 4, 2024, reporter Bernice Lottering writes about InMed’s INM-901 Alzheimer’s disease preclinical study results and the company’s
There have been major advances in Alzheimer’s disease research and development in the past two years alone. What are those breakthroughs and what’s in development
In this video, InMed’s CEO, Eric A. Adams, explains the neuritogenesis process and how this process is essential for neuronal signaling and healthy brain functioning.
#1455 – 885 West Georgia St.
Vancouver, BC, Canada
V6C 3E8
© Copyright 2024 InMed Pharmaceuticals Inc.
"*" indicates required fields